VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+0.14%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$204M
AUM Growth
+$15.9M
(+8.5%)
Cap. Flow
+$16.5M
Cap. Flow
% of AUM
8.1%
Top 10 Holdings %
Top 10 Hldgs %
6.14%
Holding
488
New
66
Increased
245
Reduced
135
Closed
40
Top Buys
| 1 |
CrowdStrike
CRWD
|
$1.1M |
| 2 |
Netflix
NFLX
|
$1.03M |
| 3 |
Qualcomm
QCOM
|
$1.03M |
| 4 |
Royal Caribbean
RCL
|
$1M |
| 5 |
TJX Companies
TJX
|
$973K |
Top Sells
| 1 |
PXD
Pioneer Natural Resource Co.
PXD
|
$1.11M |
| 2 |
Eli Lilly
LLY
|
$937K |
| 3 |
Freeport-McMoran
FCX
|
$933K |
| 4 |
Align Technology
ALGN
|
$933K |
| 5 |
Martin Marietta Materials
MLM
|
$930K |
Sector Composition
| 1 | Financials | 26.66% |
| 2 | Healthcare | 19.14% |
| 3 | Technology | 17.16% |
| 4 | Energy | 7.21% |
| 5 | Industrials | 6.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Crinetics Pharmaceuticals
CRNX
$3.35B
| $86.5K | 0.04% |
1,931
-548
| -22% | -$24.5K |
|
377
Kura Oncology
KURA
$713M
| $86.4K | 0.04% |
4,197
-3,057
| -42% | -$62.9K |
|
378
Akero Therapeutics
AKRO
$3.58B
| $86.3K | 0.04% |
3,677
-202
| -5% | -$4.74K |
|
379
Replimune Group
REPL
$494M
| $86.1K | 0.04% |
9,569
-1,596
| -14% | -$14.4K |
|
380
Rocket Pharmaceuticals
RCKT
$354M
| $85.3K | 0.04% |
3,960
+897
| +29% | +$19.3K |
|
381
Cogent Biosciences
COGT
$1.82B
| $85K | 0.04% |
10,081
-7,386
| -42% | -$62.3K |
|
382
Zymeworks
ZYME
$1.14B
| $84.6K | 0.04% |
9,937
+332
| +3% | +$2.83K |
|
383
Precigen
PGEN
$1.3B
| $84.1K | 0.04% |
53,250
-15,514
| -23% | -$24.5K |
|
384
Beam Therapeutics
BEAM
$2.11B
| $84K | 0.04% |
3,587
+676
| +23% | +$15.8K |
|
385
Keros Therapeutics
KROS
$633M
| $83.6K | 0.04% |
1,829
-738
| -29% | -$33.7K |
|
386
Mineralys Therapeutics
MLYS
$2.7B
| $83.5K | 0.04% |
7,134
-3,367
| -32% | -$39.4K |
|
387
Alector
ALEC
$305M
| $83.4K | 0.04% |
18,362
+7,533
| +70% | +$34.2K |
|
388
Oric Pharmaceuticals
ORIC
$1.06B
| $83.3K | 0.04% |
11,787
+2,350
| +25% | +$16.6K |
|
389
Allogene Therapeutics
ALLO
$246M
| $83K | 0.04% |
35,640
+3,673
| +11% | +$8.56K |
|
390
Apogee Therapeutics
APGE
$2.26B
| $82.6K | 0.04% |
2,099
-1,628
| -44% | -$64.1K |
|
|
BLTE
391
Belite Bio
BLTE
$2.16B
| $82.5K | 0.04% |
1,807
-152
| -8% | -$6.94K |
|
|
ITOS
392
DELISTED
iTeos Therapeutics
ITOS
| $82.4K | 0.04% |
5,554
-2,492
| -31% | -$37K |
|
|
CNTA
393
Centessa Pharmaceuticals
CNTA
$2.11B
| $82.3K | 0.04% |
+9,116
| New | +$82.3K |
|
394
MacroGenics
MGNX
$126M
| $82.2K | 0.04% |
19,343
+10,034
| +108% | +$42.6K |
|
395
CG Oncology
CGON
$2.52B
| $82.1K | 0.04% |
+2,601
| New | +$82.1K |
|
396
Soleno Therapeutics
SLNO
$3.71B
| $82K | 0.04% |
2,011
-316
| -14% | -$12.9K |
|
397
IDEAYA Biosciences
IDYA
$2.38B
| $81.6K | 0.04% |
2,325
-210
| -8% | -$7.37K |
|
398
Pliant Therapeutics
PLRX
$114M
| $81.3K | 0.04% |
7,563
+2,396
| +46% | +$25.8K |
|
399
Immatics
IMTX
$761M
| $81.2K | 0.04% |
6,990
-1,847
| -21% | -$21.5K |
|
400
Arcus Biosciences
RCUS
$1.3B
| $81.1K | 0.04% |
5,325
+414
| +8% | +$6.31K |
|